Skip to main content
. Author manuscript; available in PMC: 2019 Aug 6.
Published in final edited form as: Nature. 2019 Feb 6;566(7743):270–274. doi: 10.1038/s41586-019-0916-x

Figure 1 |. Ythdf1−/− mice shows effective tumor control dependent on CD8+ T cells.

Figure 1 |

a, WT or Ythdf1−/− mice were injected s.c. with 106 B16-OVA cells. Tumor growth were monitored. One of three representative experiments is shown. b, WT or Ythdf1−/− mice were injected s.c. with 106 MC38 cells. Tumor growth was monitored. One of three representative experiments is shown. c, Percentage of tumor-infiltrating T cells and NK cells at day 12 post tumor inoculation. d, WT or Ythdf1−/− mice were injected s.c. with 106 B16-OVA cells. 200 μg of CD8- or NK-depleting antibody were administered twice a week starting on day 0. Tumor size was monitored overtime. n, numbers of mice. Data are mean ± s.e.m. and were analyzed by two-tailed unpaired Student’s t-test.